Mangoceuticals, Inc. Capital Expenditures
Mangoceuticals, Inc. (MGRX) reported Capital Expenditures of $3.52 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2025-03-20
- Mangoceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Mangoceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2023-09-30 was $0.00.
- Mangoceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2023-06-30 was $0.00.
- Mangoceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2023-03-31 was $3.52K.
- Mangoceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $3.52K, a 91.84% decline from fiscal 2022.
- Mangoceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $43.10K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $0.00 derived: sum of 3 quarters · filed 2025-03-20 | $3.52K 10-K · filed 2025-03-20 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $3.52K 10-Q · filed 2024-11-14 | $44.09K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $3.52K 10-Q · filed 2024-08-14 | $44.09K derived: sum of 3 quarters · filed 2024-08-14 | |
| 2023-03-31 | $3.52K 10-Q · filed 2024-05-15 | $44.09K derived: sum of 2 quarters · filed 2024-05-15 | ||
| 2022-12-31 | $40.57K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $43.10K 10-K · filed 2024-04-01 | ||
| 2022-09-30 | $2.53K 10-Q · filed 2023-10-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |